Home » Stocks » Synthetic Biologics

Synthetic Biologics, Inc. (SYN)

Stock Price: $0.560 USD 0.003 (0.47%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 10.89M
Revenue (ttm) n/a
Net Income (ttm) -14.09M
Shares Out 19.44M
EPS (ttm) -0.88
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $0.560
Previous Close $0.557
Change ($) 0.003
Change (%) 0.47%
Day's Open 0.550
Day's Range 0.550 - 0.576
Day's Volume 105,964
52-Week Range 0.252 - 0.750

More Stats

Market Cap 10.89M
Enterprise Value 3.43M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 19.44M
Float 19.30M
EPS (basic) -0.88
EPS (diluted) -0.88
FCF / Share -0.74
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 117,280
Short Ratio 0.17
Short % of Float 0.61%
Beta 1.97
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 77.81
Revenue n/a
Operating Income -14.37M
Net Income -14.09M
Free Cash Flow -13.65M
Net Cash 7.46M
Net Cash / Share 0.38
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -53.49%
ROE -111.53%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$1.38*
(146.43% upside)
Low
1.25
Current: $0.560
High
1.50
Target: 1.38
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue---------2.61
Gross Profit---------2.61
Operating Income-15.66-17.57-26.25-39.25-40.98-20.50-12.34-17.30-5.93-1.08
Net Income-15.30-13.37-15.17-27.26-43.74-19.78-12.32-17.07-8.15-1.71
Shares Outstanding16.446.233.552.692.311.771.301.000.790.64
Earnings Per Share-0.98-4.06-6.23-10.15-18.90-11.20-9.45-17.15-10.15-2.80
Operating Cash Flow-13.87-17.28-20.20-27.90-38.89-16.08-7.72-8.92-2.88-1.15
Capital Expenditures--0.01-0.21-0.57-0.50-0.05-0.04-0.01-0.07
Free Cash Flow-13.87-17.29-20.42-28.47-39.39-16.13-7.76-8.93-2.87-1.08
Cash & Equivalents15.0528.9217.1219.0620.8217.5314.639.956.682.65
Total Debt0.72---------
Net Cash / Debt14.3228.9217.1219.0620.8217.5314.639.956.682.65
Assets17.2430.1418.8422.5030.8519.1416.2613.427.484.11
Liabilities5.753.6910.2020.2515.849.591.030.400.420.53
Book Value1.8217.07-1.503.8516.059.5615.2313.037.063.58
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Synthetic Biologics, Inc.
Country United States
Employees 11
CEO Steven A. Shallcross

Stock Information

Ticker Symbol SYN
Stock Exchange NYSE American
Sector Healthcare
Industry Biotechnology
Unique Identifier NYSEAMERICAN: SYN
IPO Date June 26, 2006

Description

Synthetic Biologics, Inc., a clinical-stage company develops therapeutics to treat gastrointestinal diseases in the United States. Its lead product candidates include SYN-004 that has completed Phase II clinical trial designed to degrade commonly used intravenous beta-lactam antibiotics in gastrointestinal tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients. The company is also developing SYN-010 that is in Phase IIb/III clinical trial to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation; and SYN-020, an early-stage oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, its clinical stage products include SYN-006 and SYN-007 for the prevention of CDI, overgrowth of pathogenic organisms, and AMR; and SYN-005 for the prevention and treatment of pertussis. Synthetic Biologics, Inc. has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company is headquartered in Rockville, Maryland.